HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Rheumatology · Psoriatic Arthritis Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Rheumatology · Psoriatic Arthritis Therapeutic Area Assessment

14 signals · 1 insights · 35 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Low Confidence · 52%

Evidence

50 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Rheumatology · Psoriatic Arthritis integrates 14 signals, 1 executive insights, and 35 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 21, 2026

    Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients

    Eli Lilly is conducting a study to assess the safety and efficacy of baricitinib in children with systemic juvenile idiopathic arthritis.

    View detail
  2. signalJul 19, 2026

    Eli Lilly's Eloralintide Shows Promise for Osteoarthritis Knee Pain in Obese Patients

    Eli Lilly is conducting two independent studies to evaluate the efficacy and safety of Eloralintide (LY3841136) in adults with knee osteoarthritis and obesity.

    View detail
  3. signalJul 15, 2026

    Study on Pain Mechanisms in Juvenile Arthritis Launched by Washington University

    A new study is investigating the mechanisms of pain in juvenile idiopathic arthritis through psychophysical assessments and biological sampling.

    View detail
  4. signalJul 13, 2026

    Study on Lung Disease Prevalence in Early Rheumatoid Arthritis Patients

    The study aims to characterize lung disease prevalence in early rheumatoid arthritis patients and identify novel biomarkers.

    View detail
  5. regulatoryJul 21, 2026

    Clinical trials for medicines: collection, verification and reporting of safety events

    Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.

    View detail
  6. regulatoryJul 21, 2026

    Pediatric Tracking Requirements Under FDAAA

    Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Eli Lilly.

    View detail
  7. regulatoryJul 21, 2026

    Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

    This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.

    View detail
  8. regulatoryJul 21, 2026

    FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

    Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

    View detail
  9. insightJun 17, 2026

    Emerging Competitive Dynamics in Rheumatology: Focus on Psoriatic Arthritis and RA Treatments

    The continuation study of Zasocitinib is significant as it may provide critical data on long-term safety and efficacy, potentially enhancing Takeda's competitive edge in the PsA market. Monitoring this study's outcomes is essential for understanding future treatment landscape dynamics and strategic positioning. Assessment grounded in 16 ranked evidence items (6 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 1 risk-calibrated assessments for portfolio review. 35 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 3 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Clinical trials for medicines: collection, verification and reporting of safety events

    83%

    Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.

    Source: MHRA

    View evidence

  • Pediatric Tracking Requirements Under FDAAA

    72%

    Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Eli Lilly.

    Source: FDA

    View evidence

  • Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

    72%

    This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.

    Source: FDA

    View evidence

  • FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

    72%

    Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

    Source: FDA

    View evidence

  • FDA AP — MALARONE PEDIATRIC (SUPPL)

    72%

    Application NDA021078. Sponsor: GLAXOSMITHKLINE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ATOVAQUONE, PROGUANIL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    72%

    YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

    Source: FDA

    View evidence

  • Emerging Competitive Dynamics in Rheumatology: Focus on Psoriatic Arthritis and RA Treatments

    52%

    The continuation study of Zasocitinib is significant as it may provide critical data on long-term safety and efficacy, potentially enhancing Takeda's competitive edge in the PsA market. Monitoring this study's outcomes is essential for understanding future treatment landscape dynamics and strategic positioning. Assessment grounded in 16 ranked evidence items (6 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients

    Trial Update

  • Eli Lilly's Eloralintide Shows Promise for Osteoarthritis Knee Pain in Obese Patients

    Trial Update

  • Study on Pain Mechanisms in Juvenile Arthritis Launched by Washington University

    Trial Update

  • Study on Lung Disease Prevalence in Early Rheumatoid Arthritis Patients

    Trial Update

  • Phase II Study of D-0120 and Allopurinol in Gout by InventisBio

    Trial Update

  • Novartis initiates Phase II trial of MAS825 for Still's Disease

    Trial Update

  • Pilot rTMS Trial for Knee Arthritis Pain and Depression Shows Promise

    Trial Update

  • Novartis initiates ascending dose study of PIT565 for rheumatoid arthritis

    Trial Update

Insights

  • Emerging Competitive Dynamics in Rheumatology: Focus on Psoriatic Arthritis and RA Treatments

    Rheumatology · Psoriatic Arthritis

Companies

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Takeda

    4 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.